Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Nelipepimut-S · E-75 PEPTIDE

Vaccine (Peptide vaccine) · Immune activation, directed at HER2/neu (ERBB2)

Phase 2 Most advanced trial (none active)
1 Registered trials

What is Nelipepimut-S?

Nelipepimut-S is a peptide vaccine comprising a HER2/neu-derived nonapeptide restricted to HLA A2/A3. It is designed to induce cytotoxic T-lymphocyte responses against HER2/neu-expressing tumor cells. The vaccine is studied in breast cancer, typically administered with trastuzumab.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
E-75 PEPTIDE
Drug type
Vaccine (Peptide vaccine)
Targets
HER2/neu (ERBB2) (antigen)
Mechanism
Immune activation, directed at HER2/neu (ERBB2)
Pathways
immune_activation
Therapy area
Oncology
In trials of
SLS
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
7M0A29CD8B

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02297698 Phase 2 Breast Cancer Completed SLS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast Cancer

Other drugs acting on ERBB2

Neratinib FDA approved Trastuzumab Deruxtecan FDA approved Trastuzumab Emtansine FDA approved Zanidatamab FDA approved ADCT-502 Phase 1 BH-30643 Phase 1/2 CGT4255 Phase 1 CUDC-101 Phase 1 ELVN-002 Phase 1 Enozertinib Phase 1/2 NVL-330 Phase 1 TTX-MC138 Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.